Cargando…

FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?

SIMPLE SUMMARY: FAPI represents a novel class of radiotracers demonstrating promising results in terms of a high uptake in concordance with low background noise in several malignancies. Thereby, FAPI-PET/CT achieves sharp contrasts facilitating staging as well as tumor delineation and detection. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dendl, Katharina, Koerber, Stefan A., Kratochwil, Clemens, Cardinale, Jens, Finck, Rebecca, Dabir, Mardjan, Novruzov, Emil, Watabe, Tadashi, Kramer, Vasko, Choyke, Peter L., Haberkorn, Uwe, Giesel, Frederik L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508433/ https://www.ncbi.nlm.nih.gov/pubmed/34638433 http://dx.doi.org/10.3390/cancers13194946

Ejemplares similares

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT
por: Koerber, Stefan A., et al.
Publicado: (2021)

(68)Ga-FAPI-PET/CT in patients with various gynecological malignancies
por: Dendl, Katharina, et al.
Publicado: (2021)

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
por: Dendl, K., et al.
Publicado: (2021)

Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer
por: Novruzov, E., et al.
Publicado: (2022)

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [(18)F]FAPI-74 with [(18)F]FDG in Patients with PDAC: A Prospective Exploratory Study
por: Novruzov, Emil, et al.
Publicado: (2023)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

[(68) Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
por: Conen, Patrick, et al.
Publicado: (2022)

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer
por: Ristau, J., et al.
Publicado: (2020)

Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
por: Windisch, Paul, et al.
Publicado: (2021)

Activated fibroblasts in muscle sarcoidosis revealed by [(18)F]FAPI-74 PET
por: Watabe, Tadashi, et al.
Publicado: (2023)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review
por: Windisch, Paul, et al.
Publicado: (2020)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Impact of (68)Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
por: Koerber, Stefan A., et al.
Publicado: (2023)

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
por: Syed, M., et al.
Publicado: (2020)

High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
por: Kesch, Claudia, et al.
Publicado: (2021)

Radiosynthesis and First Preclinical Evaluation of the Novel (11)C-Labeled FAP Inhibitor (11)C-FAPI: A Comparative Study of (11)C-FAPIs and ((68)Ga) Ga-DOTA-FAPI-04 in a High–FAP-Expression Mouse Model
por: Wang, Cheng, et al.
Publicado: (2022)

Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer
por: Liermann, Jakob, et al.
Publicado: (2021)

Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
por: Watabe, Tadashi, et al.
Publicado: (2023)

One-pot and one-step automated radio-synthesis of [(18)F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
por: Naka, Sadahiro, et al.
Publicado: (2021)

Detecting and Locating the Site of Local Relapse Using (18)F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
por: Koerber, S. A., et al.
Publicado: (2022)

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
por: Aso, Ayaka, et al.
Publicado: (2023)

Comparison of early and late (68)Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
por: Hoppner, Jorge, et al.
Publicado: (2023)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

FAP-Specific Signalling Is an Independent Diagnostic Approach in ACC and Not a Surrogate Marker of MRI Sequences
por: Liew, Dawn P., et al.
Publicado: (2022)

FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review
por: Arçay Öztürk, Ayça, et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of (68)Ga-FAPI PET/CT
por: Sviridenko, Anna, et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gqdlfpdrl3b31hpj975i24ji5g